STAT+: After two deaths in autoimmune cell therapy trial, Artiva is shutting down

STAT PlusBiotech After two deaths in autoimmune cell therapy trial, Artiva is shutting down Cases appear unrelated to therapy but highlight questions of risk Manage alerts for this article Save this story for later Share this article By Elaine ChenOct. 27, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

You can reach Elaine on Signal at elaineywchen.70. Artiva Biotherapeutics said Tuesday that it’s winding down after two patients died in a trial testing its cell therapy for autoimmune diseases, the latest in a series of safety events that emerged in a promising research field. One participant in the Phase 2 study died from a neurological complication after receiving the treatment, an NK cell therapy.

Researchers, however, determined the death was likely not related to the cell therapy itself, but to a chemotherapy that was given before the cell therapy, Artiva said. It’s standard to give patients chemotherapies before infusing cell therapies to lower the patients’ white blood cell count and make room for the new cells.Advertisement A second participant experienced sudden death about two months after treatment. Researchers determined that this was not related to any component of the treatment process, but the cause of death has not been determined, the San Diego-based company said.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In autoimmune, biotech, Clinical trials, drug development Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Breaking News October 27, 2026 STAT Plus: FDA offers new details on quicker approval pathway for personalized gene therapies D.C. Diagnosis October 27, 2026 STAT Plus: RFK Jr. goes for broke in Iowa Advertisement The Readout October 27, 2026 STAT Plus: Nonprofit resurrects shelved gene therapy after startup shuts down Biotech October 27, 2026 STAT Plus: Pennsylvania Dutch country, tired of waiting for biopharma, builds drug company of its own First Opinion October 27, 2026 Cancer vaccines are finally here.

How do we get them to patients? Subscriber Picks